Vaxcyte, Inc. (PCVX)
NASDAQ · Healthcare
Vaxcyte, Inc. Revenue 2020–2025
Vaxcyte, Inc. annual/quarterly revenue history and growth rate from 2020 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Vaxcyte, Inc. revenue for the quarter ending March 31, 2026 was 0.
- Vaxcyte, Inc. revenue for the twelve months ending March 31, 2026 was 0.
- Vaxcyte, Inc. annual revenue for 2025 was 0.
- Vaxcyte, Inc. annual revenue for 2024 was 0.
- Vaxcyte, Inc. annual revenue for 2023 was 0.
- Vaxcyte, Inc. annual revenue for 2022 was 0.
Revenue
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Vaxcyte, Inc. (PCVX) — Frequently Asked Questions
Vaxcyte, Inc. (PCVX) is a publicly traded US company. It has a market capitalization of $6.40B. Explore PCVX's stock price, financial statements, earnings history, margins and key ratios below.
What is Vaxcyte, Inc.'s market cap?
Vaxcyte, Inc. (PCVX) has a market capitalization of $6.40B.
What is the PCVX stock price?
PCVX trades at $47.04 (+3.57% on the day).
Is PCVX profitable?
In fiscal 2025, Vaxcyte, Inc. reported net income of -$767M.